Switch to:
Also traded in: Argentina, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt N/A
ABT's Cash to Debt is ranked higher than
73% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABT: N/A )
Ranked among companies with meaningful Cash to Debt only.
ABT' s Cash to Debt Range Over the Past 10 Years
Min: 0.09  Med: 0.38 Max: N/A
Current: N/A
Equity to Asset 0.53
ABT's Equity to Asset is ranked lower than
64% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. ABT: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
ABT' s Equity to Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.44 Max: 0.59
Current: 0.53
0.37
0.59
Interest Coverage 9.98
ABT's Interest Coverage is ranked lower than
78% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. ABT: 9.98 )
Ranked among companies with meaningful Interest Coverage only.
ABT' s Interest Coverage Range Over the Past 10 Years
Min: 4.25  Med: 11.51 Max: No Debt
Current: 9.98
WACC vs ROIC
13.39%
72.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 15.27
ABT's Operating margin (%) is ranked higher than
82% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. ABT: 15.27 )
Ranked among companies with meaningful Operating margin (%) only.
ABT' s Operating margin (%) Range Over the Past 10 Years
Min: 7.14  Med: 14.66 Max: 20.27
Current: 15.27
7.14
20.27
Net-margin (%) 6.71
ABT's Net-margin (%) is ranked higher than
68% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ABT: 6.71 )
Ranked among companies with meaningful Net-margin (%) only.
ABT' s Net-margin (%) Range Over the Past 10 Years
Min: 6.71  Med: 15.23 Max: 31.3
Current: 6.71
6.71
31.3
ROE (%) 6.70
ABT's ROE (%) is ranked higher than
61% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. ABT: 6.70 )
Ranked among companies with meaningful ROE (%) only.
ABT' s ROE (%) Range Over the Past 10 Years
Min: 6.7  Med: 20.51 Max: 28.49
Current: 6.7
6.7
28.49
ROA (%) 3.47
ABT's ROA (%) is ranked higher than
64% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. ABT: 3.47 )
Ranked among companies with meaningful ROA (%) only.
ABT' s ROA (%) Range Over the Past 10 Years
Min: 3.47  Med: 8.77 Max: 12.12
Current: 3.47
3.47
12.12
ROC (Joel Greenblatt) (%) 20.79
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ABT: 20.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ABT' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 0.81  Med: 42.37 Max: 82.68
Current: 20.79
0.81
82.68
Revenue Growth (3Y)(%) -1.10
ABT's Revenue Growth (3Y)(%) is ranked lower than
66% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. ABT: -1.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ABT' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -17.9  Med: 6.4 Max: 13.7
Current: -1.1
-17.9
13.7
EBITDA Growth (3Y)(%) -4.50
ABT's EBITDA Growth (3Y)(%) is ranked lower than
63% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. ABT: -4.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ABT' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -34  Med: 1.2 Max: 31.6
Current: -4.5
-34
31.6
EPS Growth (3Y)(%) -17.40
ABT's EPS Growth (3Y)(%) is ranked lower than
76% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABT: -17.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ABT' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -65.6  Med: 4.6 Max: 125.5
Current: -17.4
-65.6
125.5
GuruFocus has detected 4 Warning Signs with Abbott Laboratories $ABT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ABT's 10-Y Financials

Financials (Next Earnings Date: 2017-04-20)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABT Guru Trades in Q1 2016

Joel Greenblatt 861,862 sh (+771.99%)
Diamond Hill Capital 10,198,087 sh (+18.28%)
First Eagle Investment 7,507,515 sh (+12.53%)
Robert Olstein 220,000 sh (+9.45%)
Murray Stahl 22,778 sh (+1.22%)
PRIMECAP Management 16,812,839 sh (+1.02%)
Mairs and Power 319,391 sh (+0.15%)
Vanguard Health Care Fund 6,027,260 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
David Carlson 600,000 sh (unchged)
Paul Tudor Jones Sold Out
Jeff Auxier 78,672 sh (-0.32%)
Pioneer Investments 1,201,725 sh (-0.93%)
Dodge & Cox 29,268 sh (-3.30%)
Richard Pzena 4,642,170 sh (-4.50%)
John Buckingham 87,087 sh (-4.83%)
Ken Fisher 15,413 sh (-10.84%)
Mario Gabelli 13,695 sh (-22.30%)
Jeremy Grantham 3,713,180 sh (-34.32%)
George Soros 419,181 sh (-36.89%)
Ray Dalio 11,400 sh (-70.66%)
Tom Russo 20,400 sh (-76.11%)
Spiros Segalas 9,668,976 sh (-2.05%)
» More
Q2 2016

ABT Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 152,221 sh (New)
Stanley Druckenmiller 385,400 sh (New)
Paul Tudor Jones 26,300 sh (New)
Ray Dalio 104,100 sh (+813.16%)
Vanguard Health Care Fund 10,508,900 sh (+74.36%)
John Buckingham 133,574 sh (+53.38%)
Mairs and Power 406,484 sh (+27.27%)
Diamond Hill Capital 11,968,670 sh (+17.36%)
Jeremy Grantham 4,345,234 sh (+17.02%)
Richard Pzena 5,327,448 sh (+14.76%)
Murray Stahl 22,978 sh (+0.88%)
Jeff Auxier 78,672 sh (unchged)
Jeremy Grantham 173,800 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Robert Olstein Sold Out
Mario Gabelli 13,685 sh (-0.07%)
PRIMECAP Management 16,478,409 sh (-1.99%)
Pioneer Investments 978,987 sh (-18.53%)
Tom Russo 16,400 sh (-19.61%)
Ken Fisher 12,387 sh (-19.63%)
George Soros 329,181 sh (-21.47%)
Westport Asset Management 145,000 sh (-27.50%)
David Carlson 420,000 sh (-30.00%)
First Eagle Investment 2,974,455 sh (-60.38%)
Joel Greenblatt 130,054 sh (-84.91%)
Spiros Segalas 7,490,086 sh (-22.53%)
» More
Q3 2016

ABT Guru Trades in Q3 2016

Jim Simons 657,300 sh (New)
Steven Cohen 606,700 sh (New)
Stanley Druckenmiller 1,068,000 sh (+177.11%)
Mairs and Power 1,089,562 sh (+168.05%)
Jeremy Grantham 4,510,348 sh (+3.80%)
Ken Fisher 12,435 sh (+0.39%)
Mario Gabelli 13,695 sh (+0.07%)
Vanguard Health Care Fund 10,508,900 sh (unchged)
David Carlson 420,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
Tom Russo 16,400 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Joel Greenblatt Sold Out
Spiros Segalas Sold Out
Jeff Auxier 78,622 sh (-0.06%)
John Buckingham 133,239 sh (-0.25%)
Diamond Hill Capital 11,875,781 sh (-0.78%)
Murray Stahl 22,628 sh (-1.52%)
Manning & Napier Advisors, Inc 149,363 sh (-1.88%)
PRIMECAP Management 15,720,699 sh (-4.60%)
Richard Pzena 5,017,660 sh (-5.81%)
Pioneer Investments 908,362 sh (-7.21%)
George Soros 259,181 sh (-21.26%)
Paul Tudor Jones 16,600 sh (-36.88%)
Ray Dalio 62,000 sh (-40.44%)
First Eagle Investment 1,271,914 sh (-57.24%)
» More
Q4 2016

ABT Guru Trades in Q4 2016

Keeley Asset Management Corp 35,610 sh (New)
Joel Greenblatt 1,010,598 sh (New)
Jim Simons 2,980,400 sh (+353.43%)
Ray Dalio 80,200 sh (+29.35%)
Mairs and Power 1,333,036 sh (+22.35%)
Ken Fisher 14,794 sh (+18.97%)
Diamond Hill Capital 12,488,011 sh (+5.16%)
Manning & Napier Advisors, Inc 154,272 sh (+3.29%)
Vanguard Health Care Fund 10,758,900 sh (+2.38%)
Paul Tudor Jones 16,800 sh (+1.20%)
Richard Pzena 5,049,688 sh (+0.64%)
David Carlson 420,000 sh (unchged)
Robert Bruce 230,915 sh (unchged)
Tom Russo 16,400 sh (unchged)
Dodge & Cox 29,268 sh (unchged)
First Eagle Investment Sold Out
Pioneer Investments Sold Out
Stanley Druckenmiller Sold Out
Steven Cohen Sold Out
John Buckingham 132,868 sh (-0.28%)
Murray Stahl 22,528 sh (-0.44%)
Mario Gabelli 13,625 sh (-0.51%)
Jeremy Grantham 4,484,944 sh (-0.56%)
PRIMECAP Management 14,859,619 sh (-5.48%)
George Soros 229,181 sh (-11.57%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:SYK, NYSE:MDT, NYSE:BSX, NAS:ISRG, NYSE:ZBH, NYSE:STJ, NYSE:EW, OTCPK:SNNUF, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, NYSE:VAR, OTCPK:SDMHF, OTCPK:CHEOY, OTCPK:CNVVY, NAS:ABMD, NAS:MASI, NAS:NUVA, OTCPK:FSPKF, OTCPK:EKTAY » details
Traded in other countries:ABT.Argentina, ABTT34.Brazil, ABT.Chile, ABL.Germany, ABT.Mexico, ABT.Switzerland, ABT.UK,
Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally. Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells coronary, endovascular, structural heart, vessel closure and other medical device products.

Guru Investment Theses on Abbott Laboratories

John Rogers Comments on Abbott Laboratories - Aug 18, 2016

In addition, cardiovascular muscle devices maker St. Jude Medical, Inc. (NYSE:STJ) popped +42.39% after a takeout offer. Specifically, Abbott Laboratories (NYSE:ABT) offered $ 46.75 in cash and 0.9 shares of Abbott stock for each share of St. Jude. The stock jumped more than 25% on the news of the offering.

From John Rogers (Trades, Portfolio)' second quarter 2016 market commentary.

Check out John Rogers latest stock trades

Mason Hawkins Comments on Abbott Laboratories - May 28, 2015

Abbott (ABT), a global healthcare company, reached our appraisal, resulting in a 120% return over our 4-year holding period. We are extremely appreciative of the value that CEO Miles White built for shareholders during our ownership.

From Mason Hawkins (Trades, Portfolio)’ Longleaf Partners Fund Q1 2015 Management Discussion.

Check out Mason Hawkins latest stock trades

Top Ranked Articles about Abbott Laboratories

Insider Buys Highlight for Week of Jan. 30 Insiders bought shares of General Electric and Abbott Laboratories
General Electric Co. (NYSE:GE): Senior Vice President Jeffrey S. Bornstein bought 5,000 shares Read more...
FDA Approves Abbott Labs' Devices for MRI Scans Patients with Assurity MRI pacemaker or Tendril MRI pacing lead can have full-body scans
Good news for heart patients implanted with Abbott Labs’ (NYSE:ABT) Assurity MRI pacemaker and Tendril MRI pacing lead. The U.S. Food and Drug Administration (FDA) has approved the two devices for total-body MRI scans. Read more...
Abbott Launches Neuropathic Pain Treatment System Company says system is superior to spinal cord stimulation
Abbott Laboratories (NYSE:ABT) announced through PR Newswire Jan. 18 that it has put on the market its Proclaim DRG Neurostimulation System, which has been created to stimulate the spinal ganglion in patients chronically affected by neuropathic pain. Read more...
Abbott Closes St. Jude Medical Deal Wednesday The purchase will add to company's EPS in 2017
Abbott Labs (NYSE:ABT) communicated through the PRNewswire on Dec. 30 that the closure of the purchase of St. Jude Medical (NYSE:STJ) for $25 billion is expected on Wednesday. Read more...
Abbott Labs to Buy St. Jude Medical for $25 Billion Company agreed on US FTC conditions for the closing of the deal
Abbott Labs (NYSE:ABT) agreed Dec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical (NYSE:STJ) for a total consideration of $25 billion. Read more...
Top Insider Buys of the Week Insiders purchase shares of Eli Lilly and TiVo
The largest insider buys during the week were for Eli Lilly and Co. (NYSE:LLY), Abbott Laboratories (NYSE:ABT), Regency Centers Corp. (NYSE:REG) and TiVo Corp. (NASDAQ:TIVO). Read more...
Abbott Laboratories Announces Quarterly Dividend Health care company increased dividend by 1.9%
The board of Abbott Laboratories (NYSE:ABT) declared through PR Newswire Friday a dividend increase for the last quarter of the year. Read more...
Abbott Laboratories CEO Buys Stock in Company Insider invests in 369,950 shares in 5 separate transactions
Miles White (Insider Trades), CEO and chairman of Abbott Laboratories (ABT), purchased 369,950 shares in the company in five transations on Nov. 10. The per share price ranged from $40.45 to $40.67. Read more...
Abbott Labs: Absorb Heart Stent Approved in Japan The bioresorbable stent was approved in the US in July
Japanese patients affected by ischemic heart disease can finally be treated with Abbott's Absorb bioresorbable heart stent. Read more...
Weekly Top Insider Buys Highlight for Week of November 4 Largest Insider Buys for Abbott Laboratories, BlackRock Inc., Newell Brands Inc. and Williams Companies Inc.
Abbott Laboratories (NYSE:ABT): Director Sally E. Blount bought 5,100 shares Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 48.05
ABT's P/E(ttm) is ranked lower than
74% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. ABT: 48.05 )
Ranked among companies with meaningful P/E(ttm) only.
ABT' s P/E(ttm) Range Over the Past 10 Years
Min: 5.78  Med: 10.95 Max: 48.05
Current: 48.05
5.78
48.05
Forward P/E 18.25
ABT's Forward P/E is ranked higher than
77% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. ABT: 18.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 62.94
ABT's PE(NRI) is ranked lower than
79% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. ABT: 62.94 )
Ranked among companies with meaningful PE(NRI) only.
ABT' s PE(NRI) Range Over the Past 10 Years
Min: 5.93  Med: 21.34 Max: 250.57
Current: 62.94
5.93
250.57
Price/Owner Earnings (ttm) 551.73
ABT's Price/Owner Earnings (ttm) is ranked lower than
98% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. ABT: 551.73 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABT' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.53  Med: 11.45 Max: 2148.5
Current: 551.73
4.53
2148.5
P/B 3.17
ABT's P/B is ranked higher than
51% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. ABT: 3.17 )
Ranked among companies with meaningful P/B only.
ABT' s P/B Range Over the Past 10 Years
Min: 1.39  Med: 2.25 Max: 3.34
Current: 3.17
1.39
3.34
P/S 3.29
ABT's P/S is ranked higher than
50% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. ABT: 3.29 )
Ranked among companies with meaningful P/S only.
ABT' s P/S Range Over the Past 10 Years
Min: 0.96  Med: 1.77 Max: 6.27
Current: 3.29
0.96
6.27
PFCF 53.59
ABT's PFCF is ranked lower than
75% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. ABT: 53.59 )
Ranked among companies with meaningful PFCF only.
ABT' s PFCF Range Over the Past 10 Years
Min: 4.38  Med: 9.62 Max: 53.59
Current: 53.59
4.38
53.59
POCF 32.50
ABT's POCF is ranked lower than
73% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. ABT: 32.50 )
Ranked among companies with meaningful POCF only.
ABT' s POCF Range Over the Past 10 Years
Min: 3.82  Med: 7.06 Max: 32.5
Current: 32.5
3.82
32.5
EV-to-EBIT 43.73
ABT's EV-to-EBIT is ranked lower than
76% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. ABT: 43.73 )
Ranked among companies with meaningful EV-to-EBIT only.
ABT' s EV-to-EBIT Range Over the Past 10 Years
Min: -214.2  Med: 15.4 Max: 5414.8
Current: 43.73
-214.2
5414.8
EV-to-EBITDA 26.43
ABT's EV-to-EBITDA is ranked lower than
71% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. ABT: 26.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 10.8 Max: 28.4
Current: 26.43
4.3
28.4
PEG 89.86
ABT's PEG is ranked lower than
95% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. ABT: 89.86 )
Ranked among companies with meaningful PEG only.
ABT' s PEG Range Over the Past 10 Years
Min: 0.44  Med: 1.1 Max: 146.21
Current: 89.86
0.44
146.21
Shiller P/E 16.06
ABT's Shiller P/E is ranked higher than
92% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 49.62 vs. ABT: 16.06 )
Ranked among companies with meaningful Shiller P/E only.
ABT' s Shiller P/E Range Over the Past 10 Years
Min: 9.03  Med: 12.83 Max: 18.04
Current: 16.06
9.03
18.04
Days Inventory 108.76
ABT's Days Inventory is ranked higher than
60% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. ABT: 108.76 )
Ranked among companies with meaningful Days Inventory only.
ABT' s Days Inventory Range Over the Past 10 Years
Min: 52.56  Med: 98.82 Max: 145.14
Current: 108.76
52.56
145.14
Days Sales Outstanding 58.11
ABT's Days Sales Outstanding is ranked higher than
63% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. ABT: 58.11 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.11  Med: 74.01 Max: 145.87
Current: 58.11
58.11
145.87
Days Payable 42.51
ABT's Days Payable is ranked lower than
64% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. ABT: 42.51 )
Ranked among companies with meaningful Days Payable only.
ABT' s Days Payable Range Over the Past 10 Years
Min: 35.38  Med: 40.74 Max: 73.71
Current: 42.51
35.38
73.71

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.34
ABT's Dividend Yield is ranked higher than
79% of the 188 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. ABT: 2.34 )
Ranked among companies with meaningful Dividend Yield only.
ABT' s Dividend Yield Range Over the Past 10 Years
Min: 1.41  Med: 4.96 Max: 7.9
Current: 2.34
1.41
7.9
Dividend Payout 1.55
ABT's Dividend Payout is ranked higher than
56% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 0.41 vs. ABT: 1.55 )
Ranked among companies with meaningful Dividend Payout only.
ABT' s Dividend Payout Range Over the Past 10 Years
Min: 0.42  Med: 0.57 Max: 13.4
Current: 1.55
0.42
13.4
Dividend Growth (3y) 22.90
ABT's Dividend Growth (3y) is ranked higher than
77% of the 75 Companies
in the Global Medical Devices industry.

( Industry Median: 9.10 vs. ABT: 22.90 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ABT' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -31.2  Med: 9 Max: 22.9
Current: 22.9
-31.2
22.9
Forward Dividend Yield 2.37
ABT's Forward Dividend Yield is ranked higher than
77% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. ABT: 2.37 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.19
ABT's Yield on cost (5-Year) is ranked lower than
63% of the 225 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. ABT: 1.19 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABT' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.72  Med: 2.53 Max: 4.03
Current: 1.19
0.72
4.03
3-Year Average Share Buyback Ratio 1.70
ABT's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. ABT: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.8  Med: -0.1 Max: 2.2
Current: 1.7
-0.8
2.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 7.94
ABT's Price/Tangible Book is ranked lower than
72% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. ABT: 7.94 )
Ranked among companies with meaningful Price/Tangible Book only.
ABT' s Price/Tangible Book Range Over the Past 10 Years
Min: 4.3  Med: 9.69 Max: 22.09
Current: 7.94
4.3
22.09
Price/Projected FCF 2.13
ABT's Price/Projected FCF is ranked lower than
51% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 2.11 vs. ABT: 2.13 )
Ranked among companies with meaningful Price/Projected FCF only.
ABT' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.38  Med: 0.85 Max: 2.13
Current: 2.13
0.38
2.13
Price/Median PS Value 1.86
ABT's Price/Median PS Value is ranked lower than
87% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. ABT: 1.86 )
Ranked among companies with meaningful Price/Median PS Value only.
ABT' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.57  Med: 1.09 Max: 1.92
Current: 1.86
0.57
1.92
Price/Peter Lynch Fair Value 8.03
ABT's Price/Peter Lynch Fair Value is ranked lower than
96% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. ABT: 8.03 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABT' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.5  Med: 1.22 Max: 8.03
Current: 8.03
0.5
8.03
Earnings Yield (Greenblatt) (%) 2.30
ABT's Earnings Yield (Greenblatt) (%) is ranked higher than
63% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. ABT: 2.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABT' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 6.25 Max: 18.5
Current: 2.3
0.1
18.5
Forward Rate of Return (Yacktman) (%) 12.36
ABT's Forward Rate of Return (Yacktman) (%) is ranked higher than
60% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. ABT: 12.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABT' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -18.7  Med: 12.8 Max: 31.9
Current: 12.36
-18.7
31.9

More Statistics

Revenue (TTM) (Mil) $20,853
EPS (TTM) $ 0.93
Beta1.54
Short Percentage of Float0.92%
52-Week Range $36.76 - 45.79
Shares Outstanding (Mil)1,726.20

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 25,724 26,180 28,836
EPS ($) 2.41 2.72 3.05
EPS w/o NRI ($) 2.41 2.72 3.05
EPS Growth Rate
(3Y to 5Y Estimate)
9.33%
Dividends Per Share ($) 1.09 1.19 1.26
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Beaten-Down Valuation and a 3% Dividend Yield Feb 07 2017 
Merck: Analyzing 2016 Performance and Outlook for 2017 Feb 04 2017 
Insider Buys Highlight for Week of Jan. 30 Feb 04 2017 
FDA Approves Abbott Labs' Devices for MRI Scans Feb 02 2017 
Is Abbott Labs or AbbVie the Better Investment? Jan 31 2017 
AbbVie Reports 4th-Quarter 2016 Results Jan 27 2017 
Abbott Laboratories Releases 4th-Quarter Results Jan 25 2017 
Abbott Laboratories: An Undervalued Diamond in Overvalued Markets Jan 24 2017 
AbbVie Increases Price of Humira Jan 23 2017 
Abbott Launches Neuropathic Pain Treatment System Jan 19 2017 

More From Other Websites
ABBOTT LABORATORIES Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Feb 17 2017
Abbott Declares 373rd Consecutive Quarterly Dividend Feb 17 2017
Real-World Data from Abbott's FreeStyle® Libre Show Association Between Higher Frequency of Glucose... Feb 15 2017
Dysfunction, Heartbreak And Love: 11 Most Interesting Corporate Couples Feb 14 2017
Abbott Laboratories may see boost from St. Jude's acquisition: Barron's Feb 12 2017
5 Trade Ideas for Monday: Abbott Labs, ARRIS, BorgWarner, Lockheed and Nasdaq Feb 12 2017
[$$] Prognosis on Abbott Labs' Stock: 20% Return Feb 11 2017
High-Powered Insiders Are Buying These 5 Stocks; Should You? Feb 08 2017
Dept. of Homeland Security Provides A Timely Update On Abbott, St. Jude Feb 07 2017
Locust Wood Boosts Exposure to These Companies Feb 06 2017
Insider Buys Highlight for Week of Jan. 30 Feb 04 2017
[$$] Robert Schoellhorn Found New Career After Serving as Abbott Labs CEO Feb 03 2017
Abbott Laboratories (ABT)’s Molecular Test For Detecting Zika Virus Approved By The FDA Feb 03 2017
[$$] Robert Schoellhorn Found New Career After Serving as Abbott Labs CEO Feb 03 2017
No "Sophomore Slump" Ahead For Boston Scientific Feb 02 2017
ETFs with exposure to Abbott Laboratories : February 2, 2017 Feb 02 2017
Abbott Laboratories (ABT) Pacemakers Get FDA Approval Feb 02 2017
FDA Approves Abbott Labs' Devices for MRI Scans Feb 02 2017
Edwards Lifesciences Sinks 9%; Is This A Buying Opportunity? Feb 02 2017
U.S. FDA Grants Abbott the First Commercial Authorization for a Molecular Test to Detect Zika Virus... Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)